94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Inflammation Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1535969
This article is part of the Research Topic Ferroptosis: Intersections, Implications, and Innovations in Programmed Cell Death View all 12 articles
Metal-phenolic Nanozyme as A Ferroptosis Inhibitor for Alleviating Cisplatininduced Acute Kidney Injury
Provisionally accepted- 1 University of Science and Technology of China, Hefei, Anhui Province, China
- 2 Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China
- 3 Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China
Cisplatin-induced acute kidney injury (AKI) is primarily caused by oxidative stress resulting from the accumulation of reactive oxygen species (ROS). Thus, the development of ROS scavengers offers promising new opportunities for preventing and treating cisplatin-induced AKI by targeting oxidative stress. Herein, we fabricate metalpolyphenol self-assembled nanozyme (Fe@Ba) for inhibiting ferroptosis by synergistic catalytic performances and antioxidant. The Fe@Ba nanozyme were constructed using metal-polyphenol coordination-driven nanoprecipitation. After being internalized by MTEC cells, Fe@Ba nanozyme demonstrates excellent catalase (CAT)-and superoxide dismutase (SOD)-like activities. which in return effectively depletes high levels of ROS in AKI model. In addition, traditional Chinese medicine of baicalein (Ba) exhibits great antioxidant and inhibits lipid peroxidation (LPO). This led to the upregulation of reductive glutathione (GSH), thereby promoting glutathione peroxidase 4 (GPX4) expression and inhibiting lethal ferroptosis. Fluorescence imaging shows that the cyanine 5.5 (Cy5.5)-labeled Fe@Ba nanozyme effectively accumulates in the kidneys, which contributes to achieving significant therapeutic outcomes. In vivo experiments confirm that Fe@Ba nanozyme reduces inflammation and enhances survival rates in an AKI model, demonstrating its therapeutic potential. This study not only validates the concept of self-assembling nanozyme but also offers new insights into the use of nanomedicine for AKI treatment, emphasizing its ability to counteract inflammationrelated damage.
Keywords: Nanozyme, Acute Kidney Injury, ferroptosis, Cisplatin, Reactive Oxygen Species
Received: 28 Nov 2024; Accepted: 24 Mar 2025.
Copyright: © 2025 Zhu, Xiong, Kang, Rao, Huang and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yang Zhu, University of Science and Technology of China, Hefei, 230026, Anhui Province, China
Lixin Wei, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.